检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]江西省儿童医院,南昌330006
出 处:《江西医药》2013年第12期1102-1104,共3页Jiangxi Medical Journal
摘 要:目的分析了解江西地区儿童白血病(AL)各免疫亚型分布规律及各亚型在不同年龄段的发生率。方法对376例我院收治的江西地区儿童AL患儿采用CD45/侧散射(SSC)双参数散点图设门方法进行流式细胞术细胞表面及浆内分化抗原分析。结果急性淋巴细胞白血病(ALL)297例,占89.6%,急性髓性白血病(AML)79例,占21.4%;ALL中B系266例,占ALL的89.6%,T系31例、占ALL的10.4%;在B系中以普通型ALL多见,占B系ALL的66.1%;在297例ALL中有65例表达髓系CD13、CD33抗原、在79例中有15例表达淋系CD19、CD3、CD10抗原;10岁以上组与10岁以下组比较、T系ALL、APL好发于年龄10岁以上组。结论我院收治的江西地区儿童AL各免疫亚型分布与国内外文献报道大致相近,T系及APL好发大于10岁儿童。Objective To investigate the lmmunophenotype distribution rule and the incidence of various subtypes in different age groups of leukemia (AL) children treated in our hospital in Jiangxi. Methods The differentiation antigen in the cell surface and plasma from 376 cases of ALL were assayed by flow cytometry analysis with the method of CD45/ side scatter (SSC) double parameters and scatter spot picture. Results 297 cases were acute lymphoblastic leukemia (ALL) (89.6%),79 cases were acute myeloid leukemia (AML)(21.4%). 266 cases were Acute B-cell lymphoblastic leukemia(B-ALL) 31 cases,accounted for 89.6% of ALL,31 cases are acute T-cell lymphoblastic leukemia(T-ALL),accounted for 10.4%of ALL. Commen B-cell acute lymphoblastic leukemia (C-B-ALL) was the most of the B-ALL,accounted for 66.1% of B-ALL.In the 297 cases of ALL,65 cases expressed myeloid antigen CD13 and CD33,In the 79 cases of AML,15 cases expressed lymphocyte antigen CD19,CD3 and CD10. The in-cidence of T-ALL and acute promyelocytic leukemia (APL)in the group over 10 years old are both higher than that under the age of 10. Conclusion The Immunophenotype distribution of AL children treated in our hospital in Jiangxi is similar to those repoted in the domestic and foreign literatures. Children over 10 years old have a higher incidence of T-ALL and APL.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.216.130.198